Haystack Oncology, an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology to optimize minimal residual disease (MRD) testing and better inform decisions around therapy, announced that it raised $56 million in Series A financing.

The financing was led by Catalio Capital Management, which co-founded Haystack through its private equity and structured equity investment vehicles. Additional investors include Bruker, Exact Ventures, the venture arm of Exact Sciences and Alexandria Venture Investments.